Close Menu

IPO

The company, which raised $460 million in an IPO in July, has developed a pipeline of selective agents, two of which have advanced to Phase I clinical trials.

RMC-4630 will be investigated in combination with an investigational ERK inhibitor in RAS-mutated solid tumors.

The precision oncology startup is gearing up to enroll patients in its tissue-agnostic Phase I/II trial for its investigational new drug BDTX-189.